Skip to main content
OTCMKTSMKTS:IGNE

Igene Biotechnology Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.11 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta0.87

Competitors

Igene Biotechnology (OTCMKTSMKTS:IGNE) Vs. NTR, MOS, SMG, CF, ICL, and AVD

Should you be buying IGNE stock or one of its competitors? Companies in the industry of "agricultural chemicals" are considered alternatives and competitors to Igene Biotechnology, including Nutrien (NTR), The Mosaic (MOS), The Scotts Miracle-Gro (SMG), CF Industries (CF), ICL Group (ICL), and American Vanguard (AVD).

Nutrien (NYSE:NTR) and Igene Biotechnology (OTCMKTSMKTS:IGNE) are both basic materials companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Profitability

This table compares Nutrien and Igene Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nutrien0.47%4.19%1.98%
Igene BiotechnologyN/AN/AN/A

Valuation and Earnings

This table compares Nutrien and Igene Biotechnology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nutrien$20.02 billion1.69$992 million$2.1727.32
Igene BiotechnologyN/AN/AN/AN/AN/A

Nutrien has higher revenue and earnings than Igene Biotechnology.

Analyst Ratings

This is a summary of recent ratings and price targets for Nutrien and Igene Biotechnology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nutrien15512.50
Igene Biotechnology0000N/A

Nutrien presently has a consensus target price of $59.3750, suggesting a potential upside of 0.14%.

Volatility and Risk

Nutrien has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Igene Biotechnology has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Institutional and Insider Ownership

61.9% of Nutrien shares are held by institutional investors. 3.1% of Nutrien shares are held by company insiders. Comparatively, 90.6% of Igene Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Nutrien beats Igene Biotechnology on 8 of the 9 factors compared between the two stocks.

The Mosaic (NYSE:MOS) and Igene Biotechnology (OTCMKTSMKTS:IGNE) are both basic materials companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Insider and Institutional Ownership

69.8% of The Mosaic shares are owned by institutional investors. 0.5% of The Mosaic shares are owned by insiders. Comparatively, 90.6% of Igene Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares The Mosaic and Igene Biotechnology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Mosaic$8.91 billion1.48$-1,067,400,000.00$0.19182.53
Igene BiotechnologyN/AN/AN/AN/AN/A

Igene Biotechnology has lower revenue, but higher earnings than The Mosaic.

Volatility and Risk

The Mosaic has a beta of 1.81, meaning that its stock price is 81% more volatile than the S&P 500. Comparatively, Igene Biotechnology has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for The Mosaic and Igene Biotechnology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Mosaic171002.50
Igene Biotechnology0000N/A

The Mosaic presently has a consensus target price of $30.0882, suggesting a potential downside of 13.24%.

Profitability

This table compares The Mosaic and Igene Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Mosaic-13.05%N/AN/A
Igene BiotechnologyN/AN/AN/A

Summary

The Mosaic beats Igene Biotechnology on 4 of the 6 factors compared between the two stocks.

The Scotts Miracle-Gro (NYSE:SMG) and Igene Biotechnology (OTCMKTSMKTS:IGNE) are both basic materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for The Scotts Miracle-Gro and Igene Biotechnology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Scotts Miracle-Gro00313.25
Igene Biotechnology0000N/A

The Scotts Miracle-Gro presently has a consensus target price of $258.3333, indicating a potential upside of 13.10%.

Profitability

This table compares The Scotts Miracle-Gro and Igene Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Scotts Miracle-Gro9.38%52.60%11.09%
Igene BiotechnologyN/AN/AN/A

Volatility & Risk

The Scotts Miracle-Gro has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Igene Biotechnology has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Valuation and Earnings

This table compares The Scotts Miracle-Gro and Igene Biotechnology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Scotts Miracle-Gro$4.13 billion3.08$387.40 million$7.2431.55
Igene BiotechnologyN/AN/AN/AN/AN/A

The Scotts Miracle-Gro has higher revenue and earnings than Igene Biotechnology.

Insider and Institutional Ownership

63.1% of The Scotts Miracle-Gro shares are held by institutional investors. 27.2% of The Scotts Miracle-Gro shares are held by company insiders. Comparatively, 90.6% of Igene Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

The Scotts Miracle-Gro beats Igene Biotechnology on 8 of the 9 factors compared between the two stocks.

CF Industries (NYSE:CF) and Igene Biotechnology (OTCMKTSMKTS:IGNE) are both basic materials companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current recommendations for CF Industries and Igene Biotechnology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CF Industries15902.53
Igene Biotechnology0000N/A

CF Industries presently has a consensus target price of $47.7273, indicating a potential downside of 10.91%.

Volatility & Risk

CF Industries has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Igene Biotechnology has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Insider & Institutional Ownership

91.0% of CF Industries shares are owned by institutional investors. 2.0% of CF Industries shares are owned by insiders. Comparatively, 90.6% of Igene Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares CF Industries and Igene Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CF Industries7.00%5.14%2.34%
Igene BiotechnologyN/AN/AN/A

Earnings & Valuation

This table compares CF Industries and Igene Biotechnology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CF Industries$4.59 billion2.50$493 million$1.9327.76
Igene BiotechnologyN/AN/AN/AN/AN/A

CF Industries has higher revenue and earnings than Igene Biotechnology.

Summary

CF Industries beats Igene Biotechnology on 7 of the 8 factors compared between the two stocks.

ICL Group (NYSE:ICL) and Igene Biotechnology (OTCMKTSMKTS:IGNE) are both basic materials companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ICL Group and Igene Biotechnology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ICL Group03002.00
Igene Biotechnology0000N/A

ICL Group presently has a consensus target price of $6.1667, suggesting a potential downside of 7.82%.

Earnings & Valuation

This table compares ICL Group and Igene Biotechnology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ICL Group$5.27 billion1.62$475 million$0.3718.08
Igene BiotechnologyN/AN/AN/AN/AN/A

ICL Group has higher revenue and earnings than Igene Biotechnology.

Risk and Volatility

ICL Group has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Igene Biotechnology has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares ICL Group and Igene Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ICL Group-0.12%5.99%2.56%
Igene BiotechnologyN/AN/AN/A

Institutional and Insider Ownership

7.4% of ICL Group shares are held by institutional investors. 90.6% of Igene Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

ICL Group beats Igene Biotechnology on 5 of the 7 factors compared between the two stocks.

Igene Biotechnology (OTCMKTSMKTS:IGNE) and American Vanguard (NYSE:AVD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Risk and Volatility

Igene Biotechnology has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, American Vanguard has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Valuation and Earnings

This table compares Igene Biotechnology and American Vanguard's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Igene BiotechnologyN/AN/AN/AN/AN/A
American Vanguard$468.19 million1.28$13.60 million$0.4642.13

American Vanguard has higher revenue and earnings than Igene Biotechnology.

Insider & Institutional Ownership

76.5% of American Vanguard shares are held by institutional investors. 90.6% of Igene Biotechnology shares are held by insiders. Comparatively, 5.3% of American Vanguard shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Igene Biotechnology and American Vanguard, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Igene Biotechnology0000N/A
American Vanguard00203.00

American Vanguard has a consensus target price of $23.50, indicating a potential upside of 21.26%.

Profitability

This table compares Igene Biotechnology and American Vanguard's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Igene BiotechnologyN/AN/AN/A
American Vanguard2.40%3.16%1.61%

Summary

American Vanguard beats Igene Biotechnology on 7 of the 8 factors compared between the two stocks.


Igene Biotechnology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Nutrien logo
NTR
Nutrien
1.7$59.29flat$33.81 billion$20.02 billion348.76Analyst Report
Analyst Revision
The Mosaic logo
MOS
The Mosaic
1.7$34.68flat$13.15 billion$8.91 billion-12.08Analyst Report
The Scotts Miracle-Gro logo
SMG
The Scotts Miracle-Gro
1.9$228.41flat$12.72 billion$4.13 billion33.54Insider Selling
Analyst Revision
CF Industries logo
CF
CF Industries
2.0$53.57flat$11.49 billion$4.59 billion40.58Analyst Report
ICL Group logo
ICL
ICL Group
1.6$6.69flat$8.56 billion$5.27 billion18.08Earnings Announcement
Dividend Increase
Analyst Report
Analyst Revision
News Coverage
American Vanguard logo
AVD
American Vanguard
1.4$19.38flat$597.45 million$468.19 million52.38
Bioceres Crop Solutions logo
BIOX
Bioceres Crop Solutions
0.5$15.12flat$582.12 million$173.09 million168.00
CVR Partners logo
UAN
CVR Partners
0.4$50.96flat$544.30 million$404.18 million-5.42
Marrone Bio Innovations logo
MBII
Marrone Bio Innovations
1.3$1.42flat$248.91 million$29.37 million-7.47
Calyxt logo
CLXT
Calyxt
1.6$3.83flat$142.48 million$7.30 million-2.88Analyst Upgrade
Analyst Revision
China Green Agriculture logo
CGA
China Green Agriculture
0.8$16.82flat$106.81 million$249.24 million-0.63Upcoming Earnings
News Coverage
Wynnstay Group logo
WYN
Wynnstay Group
1.2$470.00flat£94.35 million£431.40 million17.03News Coverage
Evogene logo
EVGN
Evogene
1.3$3.30flat$84.98 million$750,000.00-4.07
BNET
Bion Environmental Technologies
0.6$1.49flat$53.66 millionN/A0.00Gap Up
EDEN
Eden Research
0.5$13.75flat£52.30 million£2.21 million-19.64
Kiwa Bio-Tech Products Group logo
KWBT
Kiwa Bio-Tech Products Group
0.6$0.01flat$8.55 million$40.09 million-0.04Gap Up
SenesTech logo
SNES
SenesTech
1.5$1.53flat$7.80 million$140,000.00-0.20
Cavitation Technologies logo
CVAT
Cavitation Technologies
0.5$0.05flat$0.00N/A0.00
China Agri-Business logo
CHBU
China Agri-Business
0.0$0.01flat$0.00N/A0.00Gap Down
Nufarm logo
NUF
Nufarm
0.9N/AN/A$0.00$1.60 billion0.00Upcoming Earnings
High Trading Volume
Gap Down
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.